- Conditions
- Pain
- Interventions
- Group A: Saline Group, Group B: 1% Ketamine group
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Pain
- Interventions
- Wafermine, Oxycodone, Placebo
- Drug
- Lead sponsor
- iX Biopharma Ltd.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
- Interventions
- Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
- Drug · Behavioral · Other
- Lead sponsor
- Brian Anderson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Treatment Resistant Depressive Disorder
- Interventions
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 20 Years to 64 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
- Conditions
- Posttraumatic Headache, Posttraumatic Stress Disorder
- Interventions
- Group A active comparator, Group B active comparator, Group C Experimental, Group D Placebo Comparator
- Procedure · Drug · Combination Product + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Fort Bragg, North Carolina
- Conditions
- Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
- Interventions
- NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
- Drug
- Lead sponsor
- NeuroRx, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more